Compare Illumina, Inc. (ILMN) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs iShares MSCI India ETF — how do they compare? Illumina, Inc. trades at $264.95 (market cap $39.95B), while iShares MSCI India ETF trades at $45.92 (market cap $5.73B). The key difference: Illumina, Inc. is far larger — about 7× iShares MSCI India ETF's market cap, and Illumina, Inc. is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and iShares MSCI India ETF for 57 Days on average.
| ILMN | INDA | |
|---|---|---|
Market Cap | $39.95B | $5.73B |
Volume | 3,169,503 | 6,797,522 |
Sector | Health | Broad Market / Factor |
52-Week High | $293.69 | $55.29 |
52-Week Low | $91.00 | $45.42 |
Typical Hold Time | 83 Days | 57 Days |
Enterprise Value | $41.31B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
INDA is trading at $46.12, down 1.31% with bearish technical signals dominating. The ETF faces headwinds from India's economic challenges including coal power shortages, monsoon concerns, and U.S. tariff tensions. Technical indicators show oversold conditions with RSI readings below 30, while moving averages signal strong bearish momentum. Recent news highlights structural issues in India's banking-heavy market composition despite overall economic growth.
The outlook remains cautious given India's energy security challenges and external trade pressures. Investment opportunity exists for long-term investors betting on India's growth story at current discounted levels, but risks include persistent power shortages, agricultural output concerns, and global trade tensions that could further pressure the ETF's performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
